

**Press Release**  
November 11, 2024

## Scandion Oncology – Interim Report Q3 2024

Scandion Oncology (Scandion) today announces its Interim Report Q3 2024. The following is taken from the report.

**Francois Martelet, CEO:**

“Business development and partnering activities remains our focus and has our top priority”

### Key Figures & Highlights

<b>TDKK</b>	<b>Q3 2024</b>	<b>Q1-Q3 2024</b>	<b>Q3 2023</b>	<b>Q1-Q3 2023</b>	<b>FY 2023</b>
<b>Operating loss</b>	<b>-7,695</b>	<b>-27,153</b>	<b>-10,910</b>	<b>-34,202</b>	<b>-45,357</b>
Net finance income/cost	-248	170	355	487	654
<b>Loss before tax</b>	<b>-7,943</b>	<b>-26,983</b>	<b>-10,555</b>	<b>-33,715</b>	<b>-44,704</b>
<b>Net loss</b>	<b>-6,750</b>	<b>-21,483</b>	<b>-10,153</b>	<b>-28,215</b>	<b>-39,204</b>
<b>Total assets</b>	<b>28,386</b>	<b>28,386</b>	<b>50,832</b>	<b>50,832</b>	<b>34,560</b>
<b>Cash Position</b>	<b>14,810</b>	<b>14,810</b>	<b>36,330</b>	<b>36,330</b>	<b>26,520</b>
<b>Total equity</b>	<b>23,701</b>	<b>23,701</b>	<b>42,111</b>	<b>42,111</b>	<b>31,122</b>
Equity ratio	83%	83%	83%	83%	90%
Earnings per share (EPS)	-0.03	-0.09	-0.25	-0.69	-0.96
Shares outstanding, ending	231,928,544	231,928,544	40,706,972	40,706,972	40,706,972

### Highlights during Q3 2024

- On July 1, Scandion board member Michel Ducreux stepped down due to ESMO scientific society’s guidelines prohibiting such board positions. He joined the advisory board.
- On August 16, Scandion Oncology achieved Maximum Tolerated Dose (MTD) for CORIST part 3. The established MTD for a 4-Days schedule of SCO-101 in combination with FOLFIRI was found to be 250 mg daily SCO-101, 50% irinotecan and 100% Leucovorin and 5-FU.
- On August 19, Scandion announced that the top priority following the very encouraging part 3 CORIST data is business development and partnering activities. As part of these efforts, Scandion is working together with Back Bay Life Science Advisors LLC, a prominent life

Scandion Oncology A/S – Symbion Fruebjergvej 3 – DK 2100 Copenhagen – Denmark  
www.scandiononcology.com – CVR No. 38613391



sciences investment banking firm, to explore and evaluate actionable strategic and financial alternatives.

### Highlights after the end of the period

- On October 31, Scandion announced that the exercise price for the warrants of series TO 2 has been determined to SEK 0,12 and that the exercise period is between November 4-18, 2024.

The Interim Report Q2 2024 is available on the Company's website: [www.scandiononcology.com](http://www.scandiononcology.com).

### Audiocast today, November at 09:00 am CET

Today at 09:00, Scandion Oncology's executive management will host a webcast and conference call presenting the results and a company update.

At the end of the presentation there will be a Q&A session.

Access to the event can be obtained as follows:

### LIVE access today Monday, November 11, 2024, at 09:00 CET:

<https://financialhearings.com/event/48943>

### REPLAY access

Webcast replay will be available at [www.scandiononcology.com](http://www.scandiononcology.com) in the Investors section and at [www.financialhearings.com](http://www.financialhearings.com)

### For further information please contact:

Johnny Stilou, CFO

Phone: +45 2960 3532

E-mail: [jos@scandiononcology.com](mailto:jos@scandiononcology.com)

The information was provided by the contact person above for publication on November 11, 2024, at 07.00 CET.

### About Scandion Oncology

Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance.

Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion's lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer.

Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market